Candel Therapeutics (CADL) vs Fennec Pharmaceuticals (FENC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed Candel Therapeutics (CADL) over the past year, gaining 66.1% versus a gain of 10.8%. Over five years, FENC leads with a +35.8% price change compared with -48.5% for CADL. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $395.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | FENC |
|---|---|---|
| Share price | $5.04 | $13.09 |
| Market cap | $395.37M | $462.14M |
| 1-day change | -1.75% | -2.68% |
| YTD return | -10.80% | +70.00% |
| 1-year return | +10.77% | +66.12% |
| 5-year return | -48.47% | +35.79% |
| P/E ratio (TTM) | — | 436.33 |
| Forward P/E | — | 12.47 |
| EPS (TTM) | $-1.53 | $0.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $44.64M |
| Revenue growth (YoY) | — | -6.09% |
| Net income (latest FY) | $-38.18M | $-9.74M |
| Operating margin | — | -14.07% |
| Net margin | — | -21.82% |
| 52-week high | $14.00 | $13.85 |
| 52-week low | $4.35 | $5.65 |
| Distance from 52-week high | -64.00% | -5.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +250.60% | +34.45% |
| Average volume | 1.26M | 220.87K |
| Shares outstanding | 78.45M | 35.31M |
| Employees | 55 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed CADL by 55.3 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
CADL vs FENC FAQ
Which is bigger, Candel Therapeutics or Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $395.37M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, CADL or FENC?
FENC returned +66.12% over the past 12 months, compared with +10.77% for CADL (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Fennec Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.